04.04.2012 - After signing a broad licensing deal with Amgen Inc. that involves five experimental compounds, AstraZeneca is looking for partnerships with industry peers.
London/Stockholm – Martin Mackay, head of research at the London-headquartered drugmaker, which conducts its R&D in Sweden, said he was also considering smaller acquisitions, product licensing deals and more partnerships with big biotech and big pharma. The deal with Amgen buys rights to jointly develop and sell five of the US biotech major's experimental autoimmune drugs, and follows a similar tie-up in diabetes five years ago with Bristol-Myers Squibb. Amgen and AstraZeneca decided to jointly develop and commercialise five of Amgen's mAbs in the field of inflammation. The deal includes the anti-IL17R mAb brodalumab which will begin phase III testing this year in psoriasis. The monoclonal antibody is also being tested in phase II to treat psoriatic arthritis and asthma. The shared portfolio also includes: AMG 139, an undisclosed mAb in Phase Ib testing for Crohn's disease, AMG 157, a mAb in phase Ib testing for asthma and atopic dermatitis, AMG 181, an undisclosed mAb in Phase Ib testing for ulcerative colitis and Crohn's disease and finally AMG 557, a mAb in phase I for systemic lupus erythematosus (SLE). Amgen receives $50m upfront. The partners and will share costs and profits. The British-Swedish company will fund two thirds of costs until 2014, after which the partners will split costs equally. Amgen and AstraZeneca will share profits equally. AstraZeneca is in the lead for the development and commercialisation of AMG 139, AMG 157 and AMG 181, while its US partner is responsible for brodalumab and AMG 557. Analysts expect that AstraZeneca alone will invest about $250m in 2013 and 2014. However, the company declined to comment those numbers. The drugmaker is suffering from recent product failure and shrinking revenues. Mackay announced the intention to close other similar deals by the end of the year.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.